NEXGEL Past Earnings Performance

Past criteria checks 0/6

NEXGEL's earnings have been declining at an average annual rate of -20.1%, while the Medical Equipment industry saw earnings growing at 13.6% annually. Revenues have been growing at an average rate of 15.4% per year.

Key information

-20.1%

Earnings growth rate

64.6%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate15.4%
Return on equity-42.3%
Net Margin-76.7%
Next Earnings Update28 Mar 2024

Recent past performance updates

Recent updates

NexGel: Old Wine In A New Bottle

Jan 30

Revenue & Expenses Breakdown
Beta

How NEXGEL makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:NXGL Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 234-330
30 Jun 233-330
31 Mar 232-430
31 Dec 222-530
30 Sep 222-630
30 Jun 222-630
31 Mar 222-530
31 Dec 212-430
30 Sep 211-320
30 Jun 211-320
31 Mar 211-220
31 Dec 201-220
30 Sep 201-220
30 Jun 201-110
31 Mar 201-220
31 Dec 191-220
30 Sep 191-220
30 Jun 191-330
31 Mar 192-220
31 Dec 182-220
30 Sep 182-120
31 Dec 172-110
31 Dec 162-220

Quality Earnings: NXGL is currently unprofitable.

Growing Profit Margin: NXGL is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: NXGL is unprofitable, and losses have increased over the past 5 years at a rate of 20.1% per year.

Accelerating Growth: Unable to compare NXGL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NXGL is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (8.7%).


Return on Equity

High ROE: NXGL has a negative Return on Equity (-42.34%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.